Replies to post #20171 on Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

"It must be balanced against the burn rate to ensure Advaxis doesn't screw over existing shareholders by dilution. Seems like a balancing act for sure. Hope DO's up to the task...."

With all due respect MP, given the price we are at now relative to the $12 recapitalization of the company over the last four years and all the dilutive capital raises plus large dilutive share grants to fund management bonuses despite lack of shareholder performance, I think "to date" the facts are that DO's balancing act has been more on the side of screwing existing shareholders. I am hopeful that will change, as his recent interview was very encouraging and reading between the lines I think we could see some big upcoming developments that take us back to more of a higher fair valuation.

[blueyedcatch]

Ok,but think about this-- The Axal Eu deal should bring a huge upfront cash payment,without any shares in the deal hopefully,because getting in on the technology should be enough for Astra or whoever,especially considering Adxs has done all the heavy lifting. So with the upfront payment for Eu Axal,I`m sure adxs is thinking they`ll have ample cash for new irons on the fire after that deal,so that sounds fine to me..Never mind the fact that Dan might have gotten a true glimpse of what`s to come with a new FDA,which may include Adxs for so many applications,which are all with Adxs`s Lysteria in combo with other approved drugs,so maybe we can get other applications pretty much rubber stamped approved. Once we get approval for Axal the ball is a rolling in that direction.

[tx_farmer]

Mpreorder, I recently have taken a position in Nabriva (NBRV). I would greatly appreciate your thoughts, given your profession. Better yet,would be a private reply.